HLX26 vs Relatlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: LAG-3 · full Non-Small Cell Lung Cancer pipeline
HLX26
Developed by Shanghai Henlius Biotech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Relatlimab
Marketed by Bristol-Myers Squibb and partners
NCT04623775 · Phase 2 · completed
The trial was randomized, triple-blind, and active-controlled, with 468 participants, and its primary efficacy endpoint was a clinical tumor-response measure. However, neither the Part 2 objective response comparison nor the Part 1 primary safety comparison was statistically significant, so the results provide well-designed but inconclusive evidence for relatlimab.
Next expected readout: January 2027 · NCT05176483 (registry estimate)
Reported efficacy
TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1 (from first dose to 12 weeks after first dose); ORR Per RECISTS v1.1 by BICR in Part 2 (Approximately 14.8 Months): Part 2 objective response rate by BICR (RECIST 1.1): nivolumab + relatlimab + chemotherapy 50.6% (90% CI 43.8 to 57.4, n=158) vs nivolumab + chemotherapy 43.0% (90% CI 36.2 to 50.1, n=151); odds ratio 1.39 (90% CI 0.94 to 2.05). The Part 1 co-primary (TRAEs leading to discontinuation within 12 weeks) compares two relatlimab regimens: 5.6% vs 12.1% (CT.gov posted results). (missed)
Result source: NCT04623775
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HLX26 | Relatlimab |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT06561386 |
| OS, median | —Not reported | —Trial running · NCT06561386 |
| ORR | —Not reported | 50.6% vs 43%vs Nivolumab + ChemotherapyNCT04623775 |
| Duration of response, median | —Not reported | 8.4 vs 7.1vs Nivolumab + ChemotherapyNCT04623775 |
PFS, median
- HLX26
- —Not reported
- Relatlimab
- —Trial running · NCT06561386
OS, median
- HLX26
- —Not reported
- Relatlimab
- —Trial running · NCT06561386
ORR
- HLX26
- —Not reported
- Relatlimab
- 50.6% vs 43%vs Nivolumab + ChemotherapyNCT04623775
Duration of response, median
- HLX26
- —Not reported
- Relatlimab
- 8.4 vs 7.1vs Nivolumab + ChemotherapyNCT04623775
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HLX26: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HLX26: 0 of 4 rows · Relatlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Relatlimab |
|---|---|
| Dropout rate | 2.5%Part 1: Treatment Aa NCT04623775 · Phase 2 · combination show 1 more result0%Part 2: Treatment C NCT04623775 · Phase 2 · combination |
| Discontinued due to AEs | —Part 1: Treatment Aa NCT04623775 · Phase 2 · combination show 1 more result—Part 2: Treatment C NCT04623775 · Phase 2 · combination |
| Serious AEs | 59.7%Part 1: Treatment Aa NCT04623775 · Phase 2 · combination show 1 more result65.2%Part 2: Treatment C NCT04623775 · Phase 2 · combination |
| Most frequent reported AEs | show 1 more result |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Relatlimab
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX26's landscape · Relatlimab's landscape